Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies

Marcelo C. Pasquini; Mei-Jie Zhang; Bruno C. Medeiros; Philippe Armand; Zhen-Huan Hui; Taiga Nishihori; Mahmoud D. Aljurf; Goerguen Akpek; Jean-Yves Cahn; Mitchell S. Cairo; Jan Cerny; Edward A. Copelan; Abhinav Deol; Cesar O. Freytes; Robert Peter Gale; Siddhartha Ganguly; Biju George; Vikas Gupta; Gregory A. Hale; Rammurti T. Kamble; Thomas R. Klumpp; Hillard M. Lazarus; Selina M. Luger; Jane L. Liesveld; Mark R. Litzow; David I. Marks; Rodrigo Martino; Maxim Norkin; Richard F. Olsson; Betul Oran; Attaphol Pawarode; Michael A. Pulsipher; Muthalagu Ramanathan; Ran Reshef; Ayman Saad; Wael Saber; Bipin N. Savani; Harry C. Schouten; Olle Ringden; Martin S. Tallman; Geoffrey L. Uy; William A., Jr. Wood; Baldeep M. Wirk; Waleska S. Perez; Minoo Batiwalla; Daniel J. Weisdorf

doi:10.1016/j.bbmt.2015.08.024

Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies

Marcelo C. Pasquini^*, Mei-Jie Zhang, Bruno C. Medeiros, Philippe Armand, Zhen-Huan Hui, Taiga Nishihori, Mahmoud D. Aljurf, Goerguen Akpek, Jean-Yves Cahn, Mitchell S. Cairo, Jan Cerny, Edward A. Copelan, Abhinav Deol, Cesar O. Freytes, Robert Peter Gale, Siddhartha Ganguly, Biju George, Vikas Gupta, Gregory A. Hale, Rammurti T. KambleThomas R. Klumpp, Hillard M. Lazarus, Selina M. Luger, Jane L. Liesveld, Mark R. Litzow, David I. Marks, Rodrigo Martino, Maxim Norkin, Richard F. Olsson, Betul Oran, Attaphol Pawarode, Michael A. Pulsipher, Muthalagu Ramanathan, Ran Reshef, Ayman Saad, Wael Saber, Bipin N. Savani, Harry C. Schouten, Olle Ringden, Martin S. Tallman, Geoffrey L. Uy, William A., Jr. Wood, Baldeep M. Wirk, Waleska S. Perez, Minoo Batiwalla, Daniel J. Weisdorf

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenetically defined groups (AML, n = 3360; MDS, n = 1373) as reported to the Center for International Blood and Marrow Transplant Research from 1998 to 2011. MK+AML was associated with higher disease relapse (hazard ratio, 1.98; P < .01), similar transplantation-related mortality (TRM) (hazard ratio, 1.01; P = .90), and worse survival (hazard ratio, 1.67; P < .01) compared with those outcomes for other cytogenetically defined AML. Among patients with MDS, MK+ MDS was associated with higher disease relapse (hazard ratio, 2.39; P < .01), higher TRM (hazard ratio, 1.80; P < .01), and worse survival (HR, 2.02; P < .01). Subset analyses comparing chromosome 7 abnormalities (del7/7q) with or without MK+ demonstrated higher mortality for MK+ disease in for both AML (hazard ratio, 1.72; P < .01) and MDS (hazard ratio, 1.79; P < .01). The strong negative impact of MK+ in myeloid malignancies was observed in all age groups and using either myeloablative or reduced-intensity conditioning regimens. Alternative approaches to mitigate disease relapse in this population are needed. (C) 2016 American Society for Blood and Marrow Transplantation.

Original language	English
Pages (from-to)	248-257
Journal	Biology of Blood and Marrow Transplantation
Volume	22
Issue number	2
DOIs	https://doi.org/10.1016/j.bbmt.2015.08.024
Publication status	Published - Feb 2016

Keywords

Monosomal karyotype
Acute myeloid leukemia
Myelodysplastic syndrome
Allogeneic transplantation

Access to Document

10.1016/j.bbmt.2015.08.024Licence: CC BY-NC-ND

Cite this

Pasquini, M. C., Zhang, M.-J., Medeiros, B. C., Armand, P., Hui, Z.-H., Nishihori, T., Aljurf, M. D., Akpek, G., Cahn, J.-Y., Cairo, M. S., Cerny, J., Copelan, E. A., Deol, A., Freytes, C. O., Gale, R. P., Ganguly, S., George, B., Gupta, V., Hale, G. A., ... Weisdorf, D. J. (2016). Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 22(2), 248-257. https://doi.org/10.1016/j.bbmt.2015.08.024

@article{c74bbad6b3a240a1919c52bdf6a108cf,

title = "Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies",

abstract = "The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenetically defined groups (AML, n = 3360; MDS, n = 1373) as reported to the Center for International Blood and Marrow Transplant Research from 1998 to 2011. MK+AML was associated with higher disease relapse (hazard ratio, 1.98; P < .01), similar transplantation-related mortality (TRM) (hazard ratio, 1.01; P = .90), and worse survival (hazard ratio, 1.67; P < .01) compared with those outcomes for other cytogenetically defined AML. Among patients with MDS, MK+ MDS was associated with higher disease relapse (hazard ratio, 2.39; P < .01), higher TRM (hazard ratio, 1.80; P < .01), and worse survival (HR, 2.02; P < .01). Subset analyses comparing chromosome 7 abnormalities (del7/7q) with or without MK+ demonstrated higher mortality for MK+ disease in for both AML (hazard ratio, 1.72; P < .01) and MDS (hazard ratio, 1.79; P < .01). The strong negative impact of MK+ in myeloid malignancies was observed in all age groups and using either myeloablative or reduced-intensity conditioning regimens. Alternative approaches to mitigate disease relapse in this population are needed. (C) 2016 American Society for Blood and Marrow Transplantation.",

keywords = "Monosomal karyotype, Acute myeloid leukemia, Myelodysplastic syndrome, Allogeneic transplantation",

author = "Pasquini, {Marcelo C.} and Mei-Jie Zhang and Medeiros, {Bruno C.} and Philippe Armand and Zhen-Huan Hui and Taiga Nishihori and Aljurf, {Mahmoud D.} and Goerguen Akpek and Jean-Yves Cahn and Cairo, {Mitchell S.} and Jan Cerny and Copelan, {Edward A.} and Abhinav Deol and Freytes, {Cesar O.} and Gale, {Robert Peter} and Siddhartha Ganguly and Biju George and Vikas Gupta and Hale, {Gregory A.} and Kamble, {Rammurti T.} and Klumpp, {Thomas R.} and Lazarus, {Hillard M.} and Luger, {Selina M.} and Liesveld, {Jane L.} and Litzow, {Mark R.} and Marks, {David I.} and Rodrigo Martino and Maxim Norkin and Olsson, {Richard F.} and Betul Oran and Attaphol Pawarode and Pulsipher, {Michael A.} and Muthalagu Ramanathan and Ran Reshef and Ayman Saad and Wael Saber and Savani, {Bipin N.} and Schouten, {Harry C.} and Olle Ringden and Tallman, {Martin S.} and Uy, {Geoffrey L.} and Wood, {William A., Jr.} and Wirk, {Baldeep M.} and Perez, {Waleska S.} and Minoo Batiwalla and Weisdorf, {Daniel J.}",

year = "2016",

month = feb,

doi = "10.1016/j.bbmt.2015.08.024",

language = "English",

volume = "22",

pages = "248--257",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Science",

number = "2",

}

Pasquini, MC, Zhang, M-J, Medeiros, BC, Armand, P, Hui, Z-H, Nishihori, T, Aljurf, MD, Akpek, G, Cahn, J-Y, Cairo, MS, Cerny, J, Copelan, EA, Deol, A, Freytes, CO, Gale, RP, Ganguly, S, George, B, Gupta, V, Hale, GA, Kamble, RT, Klumpp, TR, Lazarus, HM, Luger, SM, Liesveld, JL, Litzow, MR, Marks, DI, Martino, R, Norkin, M, Olsson, RF, Oran, B, Pawarode, A, Pulsipher, MA, Ramanathan, M, Reshef, R, Saad, A, Saber, W, Savani, BN, Schouten, HC, Ringden, O, Tallman, MS, Uy, GL, Wood, WAJ, Wirk, BM, Perez, WS, Batiwalla, M & Weisdorf, DJ 2016, 'Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies', Biology of Blood and Marrow Transplantation, vol. 22, no. 2, pp. 248-257. https://doi.org/10.1016/j.bbmt.2015.08.024

TY - JOUR

T1 - Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies

AU - Pasquini, Marcelo C.

AU - Zhang, Mei-Jie

AU - Medeiros, Bruno C.

AU - Armand, Philippe

AU - Hui, Zhen-Huan

AU - Nishihori, Taiga

AU - Aljurf, Mahmoud D.

AU - Akpek, Goerguen

AU - Cahn, Jean-Yves

AU - Cairo, Mitchell S.

AU - Cerny, Jan

AU - Copelan, Edward A.

AU - Deol, Abhinav

AU - Freytes, Cesar O.

AU - Gale, Robert Peter

AU - Ganguly, Siddhartha

AU - George, Biju

AU - Gupta, Vikas

AU - Hale, Gregory A.

AU - Kamble, Rammurti T.

AU - Klumpp, Thomas R.

AU - Lazarus, Hillard M.

AU - Luger, Selina M.

AU - Liesveld, Jane L.

AU - Litzow, Mark R.

AU - Marks, David I.

AU - Martino, Rodrigo

AU - Norkin, Maxim

AU - Olsson, Richard F.

AU - Oran, Betul

AU - Pawarode, Attaphol

AU - Pulsipher, Michael A.

AU - Ramanathan, Muthalagu

AU - Reshef, Ran

AU - Saad, Ayman

AU - Saber, Wael

AU - Savani, Bipin N.

AU - Schouten, Harry C.

AU - Ringden, Olle

AU - Tallman, Martin S.

AU - Uy, Geoffrey L.

AU - Wood, William A., Jr.

AU - Wirk, Baldeep M.

AU - Perez, Waleska S.

AU - Batiwalla, Minoo

AU - Weisdorf, Daniel J.

PY - 2016/2

Y1 - 2016/2

N2 - The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenetically defined groups (AML, n = 3360; MDS, n = 1373) as reported to the Center for International Blood and Marrow Transplant Research from 1998 to 2011. MK+AML was associated with higher disease relapse (hazard ratio, 1.98; P < .01), similar transplantation-related mortality (TRM) (hazard ratio, 1.01; P = .90), and worse survival (hazard ratio, 1.67; P < .01) compared with those outcomes for other cytogenetically defined AML. Among patients with MDS, MK+ MDS was associated with higher disease relapse (hazard ratio, 2.39; P < .01), higher TRM (hazard ratio, 1.80; P < .01), and worse survival (HR, 2.02; P < .01). Subset analyses comparing chromosome 7 abnormalities (del7/7q) with or without MK+ demonstrated higher mortality for MK+ disease in for both AML (hazard ratio, 1.72; P < .01) and MDS (hazard ratio, 1.79; P < .01). The strong negative impact of MK+ in myeloid malignancies was observed in all age groups and using either myeloablative or reduced-intensity conditioning regimens. Alternative approaches to mitigate disease relapse in this population are needed. (C) 2016 American Society for Blood and Marrow Transplantation.

AB - The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenetically defined groups (AML, n = 3360; MDS, n = 1373) as reported to the Center for International Blood and Marrow Transplant Research from 1998 to 2011. MK+AML was associated with higher disease relapse (hazard ratio, 1.98; P < .01), similar transplantation-related mortality (TRM) (hazard ratio, 1.01; P = .90), and worse survival (hazard ratio, 1.67; P < .01) compared with those outcomes for other cytogenetically defined AML. Among patients with MDS, MK+ MDS was associated with higher disease relapse (hazard ratio, 2.39; P < .01), higher TRM (hazard ratio, 1.80; P < .01), and worse survival (HR, 2.02; P < .01). Subset analyses comparing chromosome 7 abnormalities (del7/7q) with or without MK+ demonstrated higher mortality for MK+ disease in for both AML (hazard ratio, 1.72; P < .01) and MDS (hazard ratio, 1.79; P < .01). The strong negative impact of MK+ in myeloid malignancies was observed in all age groups and using either myeloablative or reduced-intensity conditioning regimens. Alternative approaches to mitigate disease relapse in this population are needed. (C) 2016 American Society for Blood and Marrow Transplantation.

KW - Monosomal karyotype

KW - Acute myeloid leukemia

KW - Myelodysplastic syndrome

KW - Allogeneic transplantation

U2 - 10.1016/j.bbmt.2015.08.024

DO - 10.1016/j.bbmt.2015.08.024

M3 - Article

C2 - 26327629

SN - 1083-8791

VL - 22

SP - 248

EP - 257

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 2

ER -